Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand.
The last earnings update was 95 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Living Cell Technologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Living Cell Technologies's
is considered below, and whether this is a fair price.
Price based on past earnings
Living Cell Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Living Cell Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Living Cell Technologies
expected to grow at an
Unable to compare Living Cell Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Living Cell Technologies's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Living Cell Technologies's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Living Cell Technologies is high growth as no earnings estimate data is available.
Unable to determine if Living Cell Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Living Cell Technologies's filings and announcements here.
Living Cell Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Living Cell Technologies
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Living Cell Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Living Cell Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Living Cell Technologies has no long term commitments.
This treemap shows a more detailed breakdown of
Living Cell Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Living Cell Technologies has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Kenneth Taylor, also known as Ken, Ph.D. has been Chief Executive Officer of Living Cell Technologies Limited since July 1, 2014 and has been its Executive Director since August 31, 2018. Dr. Taylor served as Chief Executive Officer of Antipodean Pharmaceuticals Inc. (formerly Antipodean Biotechnology Ltd.). Dr. Taylor served as Acting Chief Executive Officer and NTCELL Program Director of Living Cell Technologies Limited since February 6, 2014. He served as Medical Director and Managing Director for Roche in New Zealand. He served as Managing Director of the Roche UK affiliate since 1990 and also served at Syntex in Palo Alto, California to convert the corporate pharmaceutical company to Roche Bioscience, a research center. He managed the Roche affiliate and also to help Roche find research alliances in the Asia Pacific area. He served a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical research in Princeton, New Jersey. In 1975, he joined Roche to establish a pharmacology research and clinical pharmacology program in Sydney, Australia. He served as a Director of Antipodean Pharmaceuticals, Inc. Dr. Taylor served as Director of the Foundation for Research, Science and Technology at the New Zealand government's agency for funding scientific research. Dr. Taylor serves as an Adjunct Professor of Pharmacy at the University of Otago, Dunedin, New Zealand. Dr. Taylor has Doctorate Degrees in Pharmaceutical Chemistry and Pharmacology from the University of Otago School of Medicine. In 1986, he completed a Business Management Program at IMD in Lausanne, Switzerland. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Baltimore, Maryland.
Ken's compensation has been consistent with company performance over the past year, both up more than 20%.
Ken's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
Living Cell Technologies
management team in years:
The average tenure for the Living Cell Technologies management team is less than 2 years, this suggests a new team.
CEO & Executive Director
Co-Founder & Director
Chief Financial Officer
Chief Operating Officer
Joint Company Secretary
Joint Company Secretary
Board of Directors Tenure
Average tenure and age of the
Living Cell Technologies
board of directors in years:
The tenure for the Living Cell Technologies board of directors is about average.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company’s lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson’s disease. It has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. Living Cell Technologies Limited was founded in 1987 and is based in Melbourne, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.